Bullous Pemphigoid Following IgG/IgA Pemphigus: Possible Involvement of SGLT2 and DPP-4 Inhibitors

Authors

  • Ayano Ikeda Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, Tottori, Japan https://orcid.org/0000-0002-5902-5857
  • Naomi Tani Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, Tottori, Japan
  • Norito Ishii Department of Dermatology, Kurume University School of Medicine, Fukuoka, Japan
  • Hiroshi Koga Department of Dermatology, Kurume University School of Medicine, Fukuoka, Japan
  • Yuichi Yoshida Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, Tottori, Japan

DOI:

https://doi.org/10.2340/actadv.v106.adv-2026-0507

Keywords:

bullous pemphigoid, IgG/IgA pemphigus, DPP-4 inhibitor

Downloads

Download data is not yet available.

References

Hashimoto T, Tsuruta D, Koga H, Fukuda S, Ohyama B, Komai A, et al. Summary of results of serological tests and diagnoses for 4774 cases of various autoimmune bullous diseases consulted to Kurume University. Br J Dermatol 2016; 175: 953–965. DOI: https://doi.org/10.1111/bjd.14692

Kanwar AJ, Vinay K, Saikia UN, Koga H, Teye K, Tsuruta D, et al. IgG/IgA pemphigus reactive with desmoglein 1 with additional undetermined reactivity with epidermal basement membrane zone. Indian J Dermatol Venereol Leprol 2014; 80: 46–50. DOI: https://doi.org/10.4103/0378-6323.125499

Recke A, Rose C, Schmidt E, Bröcker EB, Zillikens D, Sitaru C. Transition from pemphigus foliaceus to bullous pemphigoid: intermolecular B-cell epitope spreading without IgG subclass shifting. J Am Acad Dermatol 2009; 61: 333–336. DOI: https://doi.org/10.1016/j.jaad.2008.10.061

Didona D, Di Zenzo G. Humoral epitope spreading in autoimmune bullous diseases. Front Immunol 2018; 9: 779. DOI: https://doi.org/10.3389/fimmu.2018.00779

Cho YT, Fu KT, Chen KL, Chang YL, Chu CY. Clinical, histopathologic, and immunohistochemical features of patients with IgG/IgA pemphigus. Biomedicines 2022; 10: 1197. DOI: https://doi.org/10.3390/biomedicines10051197

Kridin K, Bergman R. Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients. JAMA Dermatol 2018; 154: 1152–1158. DOI: https://doi.org/10.1001/jamadermatol.2018.2352

Kridin K, Cohen AD. Dipeptidyl-peptidase IV inhibitors confer an increased risk for bullous pemphigoid: a population-based study with emphasis on latency and duration of exposure. Arch Dermatol Res 2023; 315: 727–734.

Downloads

Published

2026-06-10

How to Cite

Ikeda, A., Tani, N., Ishii, N., Koga, H., & Yoshida, Y. (2026). Bullous Pemphigoid Following IgG/IgA Pemphigus: Possible Involvement of SGLT2 and DPP-4 Inhibitors. Acta Dermato-Venereologica, 106, adv–2026. https://doi.org/10.2340/actadv.v106.adv-2026-0507

Issue

Vol. 106 (2026)

Section

Short Communication

Categories

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC